Amphista Therapeutics Achieves Breakthrough in Cancer Target Degradation
Amphista Therapeutics, a leader in next-generation targeted protein degradation (TPD), has published a study in Nature Communications demonstrating a novel mechanism for degrading the key cancer target BRD9 using its proprietary Targeted Glue small molecule degrader.
"The deep expertise of our scientists led to the successful integration of the favorable performance characteristics of earlier generation PROTACs and conventional molecular glues but with key limitations designed-out." - Louise Modis, PhD, Chief Scientific Officer at Amphista Therapeutics
The company's Targeted Glues are prospectively and rationally designed medicines that have shown promising results in degrading BRD9 via a novel mechanism with DCAF16 E3 ligase.
Author's summary: Amphista Therapeutics publishes breakthrough study.
More News
- Liam Hemsworth vs. Gabriella Brooks: Who Has the Higher Net Worth?
- 2 US Navy aircraft crash in South China Sea
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- The environmental impact of the 2026 World Cup
- Wallingford deli asks for help to keep feeding people in need
- “Seeded” exhibit showcases impact of investment
- Why Hiring a Fishers Personal Injury Lawyer Is Key After a Car Accident, Slip, or Dog Bite | NorthPennNow
- Jensen Ackles back on 'Tracker' 3.2 to amp up the suspense
- BioDlink Biopharm Co., Ltd.: BioDlink Completes First International Shipment of Bevacizumab to Colombia
- READY, FIRE, AIM: Fly Me to the Moon – Pagosa Daily Post News Events & Video for Pagosa Springs Colorado